Supplement manufacturer seeks to up game in COVID-19 testing

Nutrition & Life

Garden City, NY-based ProPhase Labs, once known for making the Cold EEZE OTC remedy, moved into the manufacture of dietary supplements​ prior to the sale of that business.  ProPhase sold the Cold EEZE line to a subsidiary of Mylan NV in 2017 for a reported $50 million.

Pivoting to supplements

The company subsequently focused on the manufacture of its own line of supplements, branded as TK Supplements, as well as on its contract manufacturing capability, branded as Pharmaloz Manufacturing.

TK Supplements focuses on men’s health, with a sexual wellness product, a testosterone support product and another that aimed at prostate health.  Pharmaloz advertises the capability of manufacturing cold lozenges, pharmaceuticals as well as a broad array of dietary supplement.

Recently the company formed a third pillar, based on diagnostic testing, that saw ProPhase acquire two CLIA labs. In the news announced today, ProPhase CEO Ted Karkus said the company is forming two new subsidiaries.  One, ProPhase Precision Medicine, Inc., will focus on genomics testing technologies, while the other, ProPhase Global Healthcare, Inc., was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

Opportunity for testing in ongoing pandemic

While some other companies in and around the dietary supplement industry are seeking survive the pandemic induced market dislocations and to manage the fallout effects, Karkus said ProPhase’s testing capability can be put to good advantage.  This is especially true as the global pandemic wears on with new spikes of infections in places like the Indian subcontinent and South America.

Products You May Like

Articles You May Like

CURSO: Alimentación y Fenómeno Inmigratorio
GRAPPA Refines Recommendations on Psoriatic Disease Treatment
How to find your authentic self
EMA Seeks More Data on Myocarditis After COVID-19 Shots
Campbell Soup Co: “The name of the game for ’22 is going to be remain pretty agile and nimble”
The FDA’s big gamble on the new Alzheimer’s drug

Leave a Reply

Your email address will not be published. Required fields are marked *